Trial of High Efficiency TFF Capsule Prototype for ADC Purification

Antibody-drug conjugates (ADCs) are an emerging class of highly targeted cancer therapies in which a monoclonal antibody is chemically conjugated to a cytotoxic drug (payload). These complex biochemical moieties are comprised of three essential components: the monoclonal antibody, the payload, and the linker, which holds the moiety together. Upon targeted recognition of the specific cancer cell receptors, the antibody becomes internalized by the cell, which makes it an effective vehicle for therapy. Once the ADC has been internalized, the cytotoxic drug is released, enabling it to kill the cancerous cell. Common mechanisms of action for these drugs include microtubule inhibition and DNA damage.